LLY

834.19

+4.45%↑

UNH

616.78

+1.88%↑

JNJ

155.63

-0.71%↓

NVO

107.22

-0.35%↓

ABBV

199.85

-0.38%↓

LLY

834.19

+4.45%↑

UNH

616.78

+1.88%↑

JNJ

155.63

-0.71%↓

NVO

107.22

-0.35%↓

ABBV

199.85

-0.38%↓

LLY

834.19

+4.45%↑

UNH

616.78

+1.88%↑

JNJ

155.63

-0.71%↓

NVO

107.22

-0.35%↓

ABBV

199.85

-0.38%↓

LLY

834.19

+4.45%↑

UNH

616.78

+1.88%↑

JNJ

155.63

-0.71%↓

NVO

107.22

-0.35%↓

ABBV

199.85

-0.38%↓

LLY

834.19

+4.45%↑

UNH

616.78

+1.88%↑

JNJ

155.63

-0.71%↓

NVO

107.22

-0.35%↓

ABBV

199.85

-0.38%↓

Search

Ardelyx Inc

Suletud

Sektor Tervishoid

5.05 -20.47

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.98

Max

5.08

Põhinäitajad

By Trading Economics

Sissetulek

16M

-809K

Müük

25M

98M

Kasumimarginaal

-0.823

Töötajad

267

EBITDA

14M

2.8M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+112.82 upside

Turustatistika

By TradingEconomics

Turukapital

54M

1.4B

Eelmine avamishind

25.52

Eelmine sulgemishind

5.05

Uudiste sentiment

By Acuity

71%

29%

357 / 391 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Ardelyx Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. nov 2024, 21:42 UTC

Omandamised, ülevõtmised, äriostud

Canada May Lose Billions on Sale of Trans Mountain Pipeline

9. nov 2024, 09:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

9. nov 2024, 09:20 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

8. nov 2024, 22:31 UTC

Market Talk

Fitch Raises Spain's Outlook to Positive -- Market Talk

8. nov 2024, 22:15 UTC

Tulu

Arista's Sales of AI Data Center Networks Were Good. Investors Wanted More. -- Barrons.com

8. nov 2024, 22:01 UTC

Tulu

Constellation Software 3Q Net $164M >CSU.T

8. nov 2024, 22:01 UTC

Tulu

Constellation Software 3Q EPS $7.74 >CSU.T

8. nov 2024, 22:01 UTC

Tulu

Constellation Software 3Q Rev $2.54B >CSU.T

8. nov 2024, 22:01 UTC

Peamised uudised

Stocks Hit New Records, Close Out Best Week of the Year -- WSJ

8. nov 2024, 21:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

8. nov 2024, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

8. nov 2024, 21:29 UTC

Omandamised, ülevõtmised, äriostud

Booking Holdings Files 8K - Costs of Exits Or Disposals >BKNG

8. nov 2024, 21:26 UTC

Market Talk

Small-Business Formation Seen Driving U.S. Productivity Growth -- Market Talk

8. nov 2024, 21:25 UTC

Peamised uudised

Dow, S&P 500 Finish Their Best Week of 2024 -- WSJ

8. nov 2024, 21:04 UTC

Omandamised, ülevõtmised, äriostud

Warren Buffett Is Raising Cash -- and Missing Out on the Booming Market -- Barrons.com

8. nov 2024, 20:52 UTC

Tulu

Arista's Sales of AI Data Center Networks Were Good. Investors Wanted More. -- Barrons.com

8. nov 2024, 20:51 UTC

Omandamised, ülevõtmised, äriostud

Warren Buffett Is Raising Cash -- and Missing Out on the Booming Market -- Barrons.com

8. nov 2024, 20:51 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

8. nov 2024, 20:51 UTC

Market Talk
Tulu

Airbnb Sees Possibility to Re-enter New York City -- Market Talk

8. nov 2024, 20:33 UTC

Market Talk

U.S. Natural Gas Futures End Week Near Flat -- Market Talk

8. nov 2024, 20:15 UTC

Market Talk
Tulu

Airbnb Sees Growth Among Youngest Travelers -- Market Talk

8. nov 2024, 20:15 UTC

Market Talk

Rate Cuts, Election News May Have Lifted U.S. Consumer Expectations -- Market Talk

8. nov 2024, 19:43 UTC

Market Talk
Tulu

Molson Coors' Underperformance Partly Due to Volume Share Decline -- Market Talk

8. nov 2024, 19:40 UTC

Market Talk

Modest Gain Seen in Mexico's September Industrial Production -- Market Talk

8. nov 2024, 19:15 UTC

Market Talk

U.S. Oil Rig Count Unchanged At 479 -- Market Talk

8. nov 2024, 19:02 UTC

Peamised uudised

Dow Gains as Strong Week Nears End -- WSJ

8. nov 2024, 18:59 UTC

Peamised uudised

Goldman Pitches a Personal CFO to the Ultrawealthy -- Update

8. nov 2024, 18:40 UTC

Peamised uudised

Amazon Targets Delivery Operations in Bid for Bigger Grocery Business -- Update

8. nov 2024, 17:53 UTC

Tulu

Pinterest Sinks As Revenue Growth Underwhelms. Can Amazon And Google Help? -- IBD

8. nov 2024, 17:28 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

Võrdlus sarnastega

Hinnamuutus

Ardelyx Inc Prognoos

Hinnasiht

By TipRanks

112.82% tõus

12 kuu keskmine prognoos

Keskmine 10.79 USD  112.82%

Kõrge 13.5 USD

Madal 7 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Ardelyx Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

6

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 5.88Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

357 / 391 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ardelyx Inc

Ardelyx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines to improve treatment for people with kidney and cardiorenal diseases. The Company's product pipeline includes Tenapanor, IBSRELA, RDX013 Program, and RDX020 Program. The Tenapanor is a medicine for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor for the control of serum phosphorus has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). RDX013 Program is a small molecule potassium secretagogue program for the potential treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis. It has a discovery program targeting the inhibition of intestinal bicarbonate exchange for the treatment of metabolic acidosis.